Shots: Roche reports the new 2-year data from Part 1 of the FIREFISH study assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA. The 2-year results in infants […]readmore
Tags : Two-Year
Shots: Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future […]readmore
Shots::stosohSthShots: Almac to receive upfront, research funding, development and commercial milestones along with the royalties on sales of products emerging from the collaboration. MSD will be responsible for conducting lead […]readmore